Morgan Stanley analyst Matthew Harrison names Genmab (GMAB) a "Catalyst Driving Idea" while keeping an Underweight rating on the shares with a $34 price target. Genmab and Johnson & Johnson (JNJ) are in a second arbitration over Darzalex Faspro and a ruling is expected in 2023. The analyst reviewed the redacted copy of the license agreement and believes Genmab "may have a valid claim." The license agreement states that the milestone payments and royalties are paid on a licensed product-by-licensed product basis, and for each licensed product, royalty payments shall commence on the date of the first commercial sale of such licensed product and expiring on the later of 13 years thereafter or the expiration of relevant patents, Harrison tells investors in a research note. He says the key issue is whether Genmab is entitled to additional milestone payments and a new 13-year royalty term from Darzalex Faspro’s first commercial sale date. Harrison views Genmab’s risk/reward as favorable into the 2023 ruling.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab price target raised to DKK 3,450 from DKK 2,900 at JPMorgan
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Genmab initiated with a Market Perform at William Blair
- Society for Immunotherapy of Cancer to hold a meeting
- Genmab downgraded to Hold at Deutsche Bank ahead of ESMO and ASH data